Brian Edward Miller Sells 2,553 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Brian Edward Miller sold 2,553 shares of Intuitive Surgical stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,314,795.00. Following the completion of the sale, the executive vice president now directly owns 7,066 shares of the company’s stock, valued at approximately $3,638,990. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Intuitive Surgical Stock Down 0.2 %

ISRG opened at $511.63 on Friday. The firm’s 50 day moving average is $486.71 and its 200-day moving average is $440.96. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $523.34. The firm has a market capitalization of $181.48 billion, a P/E ratio of 92.35, a P/E/G ratio of 5.40 and a beta of 1.39.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of research analyst reports. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Leerink Partners boosted their target price on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. Stifel Nicolaus upped their price target on shares of Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a research report on Friday, October 18th. JPMorgan Chase & Co. lifted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Raymond James upped their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Institutional Investors Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its position in shares of Intuitive Surgical by 49,383.6% during the third quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock worth $535,788,000 after acquiring an additional 1,088,415 shares during the last quarter. Capital Research Global Investors acquired a new position in shares of Intuitive Surgical in the 1st quarter valued at approximately $374,390,000. Vanguard Group Inc. boosted its stake in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after buying an additional 302,382 shares in the last quarter. Finally, Strategic Financial Concepts LLC increased its stake in shares of Intuitive Surgical by 40,221.4% in the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after buying an additional 265,461 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.